219 related articles for article (PubMed ID: 22180176)
1. Impact of TP53 codon 72 and MDM2 promoter 309 allelic dosage in a Moroccan population with hepatocellular carcinoma.
Ezzikouri S; Essaid El Feydi A; Afifi R; Benazzouz M; Hassar M; Pineau P; Benjelloun S
Int J Biol Markers; 2011; 26(4):229-33. PubMed ID: 22180176
[TBL] [Abstract][Full Text] [Related]
2. MDM2 SNP309T>G polymorphism and risk of hepatocellular carcinoma: a case-control analysis in a Moroccan population.
Ezzikouri S; El Feydi AE; Afifi R; El Kihal L; Benazzouz M; Hassar M; Marchio A; Pineau P; Benjelloun S
Cancer Detect Prev; 2009; 32(5-6):380-5. PubMed ID: 19233569
[TBL] [Abstract][Full Text] [Related]
3. Interaction between p53 codon 72 and MDM2 309T>G polymorphisms and the risk of hepatocellular carcinoma.
Qiu M; Liu Y; Yu X; Qin L; Bei C; Zeng X; Qiu X; Tang B; He S; Yu H
Tumour Biol; 2016 Mar; 37(3):3863-70. PubMed ID: 26476535
[TBL] [Abstract][Full Text] [Related]
4. TP53 and MDM2 gene polymorphisms, gene-gene interaction, and hepatocellular carcinoma risk: evidence from an updated meta-analysis.
Peng Q; Lao X; Chen Z; Lai H; Deng Y; Wang J; Mo C; Sui J; Wu J; Zhai L; Yang S; Qin X; Li S
PLoS One; 2013; 8(12):e82773. PubMed ID: 24376578
[TBL] [Abstract][Full Text] [Related]
5. MDM2 promoter polymorphism is associated with increased susceptibility to hepatocellular carcinoma in Turkish population.
Akkiz H; Sümbül AT; Bayram S; Bekar A; Akgöllü E
Cancer Epidemiol; 2010 Aug; 34(4):448-52. PubMed ID: 20447891
[TBL] [Abstract][Full Text] [Related]
6. MDM2 and p53 polymorphisms are associated with the development of hepatocellular carcinoma in patients with chronic hepatitis B virus infection.
Yoon YJ; Chang HY; Ahn SH; Kim JK; Park YK; Kang DR; Park JY; Myoung SM; Kim DY; Chon CY; Han KH
Carcinogenesis; 2008 Jun; 29(6):1192-6. PubMed ID: 18390844
[TBL] [Abstract][Full Text] [Related]
7. Mdm2 Snp309 G allele displays high frequency and inverse correlation with somatic P53 mutations in hepatocellular carcinoma.
Acun T; Terzioğlu-Kara E; Konu O; Ozturk M; Yakicier MC
Mutat Res; 2010 Feb; 684(1-2):106-8. PubMed ID: 19954744
[TBL] [Abstract][Full Text] [Related]
8. Genetic polymorphisms in cell cycle regulatory genes MDM2 and TP53 are associated with susceptibility to lung cancer.
Zhang X; Miao X; Guo Y; Tan W; Zhou Y; Sun T; Wang Y; Lin D
Hum Mutat; 2006 Jan; 27(1):110-7. PubMed ID: 16287156
[TBL] [Abstract][Full Text] [Related]
9. Combined effects of p53 and MDM2 polymorphisms on susceptibility and surgical prognosis in hepatitis B virus-related hepatocellular carcinoma.
Yang Y; Xia T; Li N; Zhang J; Yang Y; Cong W; Deng Q; Lan K; Zhou W
Protein Cell; 2013 Jan; 4(1):71-81. PubMed ID: 23292895
[TBL] [Abstract][Full Text] [Related]
10. MDM2 promoter SNP309 is associated with the risk of hepatocellular carcinoma in patients with chronic hepatitis C.
Dharel N; Kato N; Muroyama R; Moriyama M; Shao RX; Kawabe T; Omata M
Clin Cancer Res; 2006 Aug; 12(16):4867-71. PubMed ID: 16914573
[TBL] [Abstract][Full Text] [Related]
11. Impact of TP53 codon 72 and MDM2 SNP 309 polymorphisms in pancreatic ductal adenocarcinoma.
Hori Y; Miyabe K; Yoshida M; Nakazawa T; Hayashi K; Naitoh I; Shimizu S; Kondo H; Nishi Y; Umemura S; Kato A; Ohara H; Inagaki H; Joh T
PLoS One; 2015; 10(3):e0118829. PubMed ID: 25734904
[TBL] [Abstract][Full Text] [Related]
12. TP53 Arg 72Pro and MDM2 SNP309 polymorphisms and colorectal cancer risk: a west Algerian population study.
Abderrahmane R; Louhibi L; Moghtit FZ; Boubekeur A; Benseddik K; Boudjema A; Benrrahal F; Aberkane M; Fodil M; Saidi-Mehtar N
Pathol Oncol Res; 2015 Jul; 21(3):629-35. PubMed ID: 25537146
[TBL] [Abstract][Full Text] [Related]
13. MDM2 SNP309 polymorphism as risk factor for susceptibility and poor prognosis in renal cell carcinoma.
Hirata H; Hinoda Y; Kikuno N; Kawamoto K; Suehiro Y; Tanaka Y; Dahiya R
Clin Cancer Res; 2007 Jul; 13(14):4123-9. PubMed ID: 17634539
[TBL] [Abstract][Full Text] [Related]
14. Effects of MDM2 promoter polymorphisms and p53 codon 72 polymorphism on risk and age at onset of squamous cell carcinoma of the head and neck.
Yu H; Huang YJ; Liu Z; Wang LE; Li G; Sturgis EM; Johnson DG; Wei Q
Mol Carcinog; 2011 Sep; 50(9):697-706. PubMed ID: 21656578
[TBL] [Abstract][Full Text] [Related]
15. Association between MDM2 SNP309, p53 Arg72Pro, and hepatocellular carcinoma risk: A MOOSE-compliant meta-analysis.
Duan X; Li J
Medicine (Baltimore); 2017 Sep; 96(36):e7856. PubMed ID: 28885338
[TBL] [Abstract][Full Text] [Related]
16. Effect of TP53 codon 72 and MDM2 SNP309 polymorphisms on survival of gastric cancer among patients who receiving 5-fluorouracil-based postoperative adjuvant chemotherapy.
Wang S; Chen L; Zhao Q; Rong H; Wang M; Gong W; Zhou J; Wu D; Zhang Z
Cancer Chemother Pharmacol; 2013 Apr; 71(4):1073-82. PubMed ID: 23423487
[TBL] [Abstract][Full Text] [Related]
17. Association of MDM2 SNP309 and TP53 Arg72Pro polymorphisms with risk of endometrial cancer.
Yoneda T; Kuboyama A; Kato K; Ohgami T; Okamoto K; Saito T; Wake N
Oncol Rep; 2013 Jul; 30(1):25-34. PubMed ID: 23624782
[TBL] [Abstract][Full Text] [Related]
18. Association of TP53 codon 72 polymorphism and the outcome of adjuvant therapy in breast cancer patients.
Toyama T; Zhang Z; Nishio M; Hamaguchi M; Kondo N; Iwase H; Iwata H; Takahashi S; Yamashita H; Fujii Y
Breast Cancer Res; 2007; 9(3):R34. PubMed ID: 17537232
[TBL] [Abstract][Full Text] [Related]
19. Investigation of the effect of MDM2 SNP309 and TP53 Arg72Pro polymorphisms on the age of onset of cutaneous melanoma.
Cotignola J; Chou JF; Roy P; Mitra N; Busam K; Halpern AC; Orlow I
J Invest Dermatol; 2012 May; 132(5):1471-8. PubMed ID: 22336942
[TBL] [Abstract][Full Text] [Related]
20. Effect of MDM2 SNP309 and p53 codon 72 polymorphisms on lung cancer risk and survival among non-smoking Chinese women in Singapore.
Chua HW; Ng D; Choo S; Lum SS; Li H; Soh LY; Sabapathy K; Seow A
BMC Cancer; 2010 Mar; 10():88. PubMed ID: 20219101
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
